An aortic sclerosis murmur is a soft-to-moderate ejection systolic sound produced by a thickened but not significantly obstructed aortic valve. It is extremely common in older adults and is often discovered incidentally during a routine physical exam. For decades, clinicians treated it as a harmless curiosity, but research over the past 25 years has shown it is not truly innocent: it signals both a valve that could eventually narrow and an elevated risk of heart attack and cardiovascular death, even when the valve itself never becomes severely diseased.
What the Murmur Sounds Like
The classic aortic sclerosis murmur is a harsh ejection systolic murmur, meaning it occurs while the heart is actively pumping blood out through the aortic valve. On a phonocardiogram, it peaks early in systole and fades well before the second heart sound, leaving a noticeable gap between the end of the murmur and the closing snap of the aortic valve.1American Heart Journal. The clinical significance of aortic sclerosis This early-peaking pattern is one of the features that helps distinguish it from the murmur of true aortic stenosis, where the peak shifts later in systole as obstruction worsens.
Auscultation findings can be confusing because the murmur is often heard not only over the traditional aortic area (the upper right chest near the sternum) but also loudly at the cardiac apex, near the bottom-left of the heart. In older patients, particularly those who also have calcification of the mitral valve ring, the murmur may actually be loudest between the third left interspace and the apex, with poor radiation up to the neck.2Gerontology. Murmurs Associated with Mitral Annular Calcification and Aortic Sclerosis That pattern can mimic mitral regurgitation at the bedside, which is why echocardiography has become the standard next step whenever clinicians hear an unexplained systolic murmur in an older person.
How It Differs from Aortic Stenosis
The boundary between aortic sclerosis and aortic stenosis is drawn by how much the valve obstructs blood flow. In aortic sclerosis, the valve leaflets are thickened and often mildly calcified, but they still open well enough that the pressure difference across the valve remains very small. Echocardiographic criteria typically define sclerosis as a peak aortic valve velocity below 2.5 meters per second with visible leaflet thickening. Once the velocity crosses that threshold, the diagnosis shifts to mild aortic stenosis, and the clinical calculus changes considerably.
A study comparing patients who stayed at the sclerosis stage with those who progressed to stenosis found that the progressors already had slightly higher baseline velocities, higher pressure gradients, more calcification, and stiffer leaflets at the time of their initial scan.3PubMed Central. Echocardiographic Progression of Calcific Aortic Valve Disease in Patients with Preexisting Aortic Valve Sclerosis In other words, the seeds of stenosis are often visible early. The murmur itself does not reliably tell you which direction things are heading, which is one reason imaging matters.
Why It Is Not an “Innocent” Murmur
The landmark study that changed how doctors think about aortic sclerosis came from the Cardiovascular Health Study, a large cohort of older Americans. Among participants who had no known coronary heart disease at the start, those with aortic sclerosis had roughly a 50 percent higher risk of dying from cardiovascular causes compared to those with normal aortic valves. Their risk of heart attack was about 40 percent higher. These elevations persisted even after researchers accounted for other cardiac risk factors.4PubMed. Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly
An important follow-up question was whether the valve thickening itself was causing these bad outcomes, or whether the sclerosis was just a sign of the same underlying disease process attacking blood vessels elsewhere. The evidence points strongly toward the latter. A study that tracked outcomes in patients with aortic sclerosis found that the increased rate of adverse cardiovascular events was tied to the presence of coronary artery disease and systemic inflammation, not to the valve problem on its own.5PubMed. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation Think of the sclerotic valve as a window into what is happening inside your arteries: the same lipid deposits, inflammatory cells, and calcification affecting the valve are likely affecting coronary and cerebral vessels too.6PubMed Central. Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk
The risk signal is not limited to community-dwelling older adults. In patients undergoing coronary artery bypass surgery, those with aortic sclerosis had roughly double the risk of in-hospital death or major complications, and their long-term mortality over about three years was also significantly elevated.7PubMed. Aortic sclerosis is associated with mortality and major morbidity in patients undergoing coronary artery bypass surgery
What Is Happening Inside the Valve
The valve changes in aortic sclerosis look strikingly similar to what happens in atherosclerotic arteries. Early on, lipids accumulate within the leaflet tissue, followed by infiltration of immune cells. Over time, collagen is deposited, the tissue stiffens, and calcium begins to accumulate.8PubMed. Statin treatment of hypercholesterolemic-induced aortic valve sclerosis The process is not simply passive calcium buildup; research has shown that cells within the valve can be actively driven toward a bone-forming state. A protein called BMP4, combined with the mechanical forces the valve experiences during each heartbeat, can push these cells to behave like bone-building cells, accelerating calcification.9Cardiovascular Research. Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis
Chronic inflammation also plays a role. In animal models, sustained inflammatory signaling through certain pathways promotes valve thickening, calcification, and even changes in heart muscle structure, particularly when kidney disease is present.10PubMed Central. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis In human studies, markers of both lipid metabolism and inflammation, including lipoprotein(a) and markers of monocyte activation, have been linked to the amount of calcium deposited on the aortic valve.11Heart. Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults
Risk Factors and Who Gets It
Aortic sclerosis is overwhelmingly a condition of aging. Population studies consistently show that older age is the strongest predictor. Beyond age, the risk factors overlap heavily with those for coronary artery disease. A 21-year follow-up of middle-aged men found that higher body mass index and the combination of high cholesterol with elevated inflammatory markers were significantly associated with developing aortic sclerosis or stenosis.12PubMed. Prevalence and risk factors of aortic stenosis and aortic sclerosis: a 21-year follow-up of middle-aged men
A population-based study added male sex, hypertension treatment, and elevated homocysteine levels to the list. Interestingly, pulse pressure (the difference between your systolic and diastolic blood pressure readings) was associated with higher velocities across the valve, hinting that the physical pounding the valve takes with each heartbeat contributes to its deterioration over time.13PubMed. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease?
How Often Does It Progress to Stenosis
Most people with aortic sclerosis will never develop hemodynamically significant aortic stenosis. A systematic review and meta-analysis calculated that roughly 1.8 to 1.9 percent of people with aortic sclerosis progress to clinical aortic stenosis each year.14PubMed. The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis That annual rate is low on an individual basis, but it accumulates: over a decade, somewhere around one in five to one in six people with sclerosis could cross the threshold into stenosis.
Identifying who will progress is an active area of research. As already noted, heavier calcification, stiffer leaflets, and mildly higher velocities at baseline all predict a worse trajectory. More recently, an algorithm that uses echocardiographic signs of diastolic dysfunction to stratify risk showed that patients with higher predicted probabilities of diastolic dysfunction were several times more likely to develop stenosis and to eventually need valve intervention or die.
Current expert guidance suggests that people with asymptomatic aortic sclerosis should have a repeat echocardiogram every five to ten years to check for progression. Once mild stenosis is present, that interval shortens to at least every three to four years because the rates of further progression climb substantially.15European Heart Journal – Cardiovascular Imaging. Outcomes of patients with early calcific aortic valve disease detected by clinically indicated echocardiography
Can Statins or Other Medications Slow It Down
Because the valve disease shares so many features with atherosclerosis, statins seemed like a logical candidate for slowing progression. The results have been largely disappointing. A dedicated study of statin-treated versus untreated patients with aortic valve sclerosis found no difference in the rate at which peak velocities increased over time.16PubMed Central. Statins Have No Role in Preventing the Progression of Aortic Valve Sclerosis A broader meta-analysis covering patients with aortic stenosis reached the same conclusion: despite consistently lowering LDL cholesterol, statins showed no effect on valve structure, function, calcification, or clinical outcomes.17Atherosclerosis. Efficacy of statins on aortic valve stenosis: A meta-analysis
There is a dissenting note worth mentioning. One observational study found that statin use in patients with aortic sclerosis was associated with lower mortality, fewer heart failure hospitalizations, and even a lower rate of progression to stenosis.18PubMed Central. The Effect of Angiotensin-Converting Enzyme Inhibitors and Statins on the Progression of Aortic Sclerosis and Mortality However, because that was observational rather than randomized, the benefit may reflect the fact that statins were treating the underlying coronary artery disease and vascular inflammation rather than protecting the valve itself. The distinction matters: statins may well improve survival in these patients because of what they do for the arteries, not because they stop the valve from calcifying. In practice, most clinicians will prescribe statins to patients with aortic sclerosis if cardiovascular risk factors warrant it, but the target is heart attack prevention, not valve preservation.
No other drug class has been shown to halt or reverse valve sclerosis. ACE inhibitors appeared to confer some benefit in the same observational study, but similarly lack randomized trial evidence for this specific indication. At present, there is no approved pharmacological therapy for slowing aortic valve calcification at any stage.
Genetic Susceptibility
Not everyone with the same cholesterol level and blood pressure develops aortic valve calcification, which points to a genetic component. Genome-wide association studies have identified a growing list of genetic regions tied to calcific aortic valve disease. One of the most consistent findings involves the lipoprotein(a), or Lp(a), gene. A variant in the LPA locus roughly doubles the odds of having aortic valve calcification, and carriers face an elevated risk of eventually developing aortic stenosis and needing valve replacement.19PubMed Central. Genetic associations with valvular calcification and aortic stenosis This is particularly relevant because Lp(a) levels are largely determined by genetics and do not respond much to diet or standard cholesterol medications, although new Lp(a)-lowering drugs are in clinical trials.
Additional loci near genes involved in valve development and vascular biology have been identified in large genetic studies. Two loci, near the genes PALMD and TEX41, are associated not only with aortic stenosis but also with bicuspid aortic valve and coronary artery disease, reinforcing the idea that valve disease and arterial disease share biological roots.20Nature Communications. Genome-wide analysis yields new loci associating with aortic valve stenosis A larger multi-ancestry study added six novel genomic regions to the list, including one near the FTO gene (best known for its role in obesity) and another near CELSR2 (implicated in cholesterol metabolism).21PubMed Central. Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program
The Anxiety Problem
There is an underappreciated psychological dimension to being told you have a heart murmur. A study that followed patients referred for echocardiography after a murmur was detected found that the majority became anxious upon hearing about the murmur. Even after a normal echocardiogram showed nothing was wrong, over half of those who had been anxious still had residual worry. Some patients began reinterpreting ordinary symptoms like chest tightness or fatigue as signs of heart disease.22BMJ. Opening Pandora’s box: the unpredictability of reassurance by a normal test result
For aortic sclerosis specifically, the challenge is even trickier. The echocardiogram is not normal; it shows a real finding. But the finding is usually mild and may never progress. Clinicians who communicate the diagnosis poorly can leave patients believing they have a serious valve problem requiring immediate intervention, or alternatively, can dismiss the finding so casually that patients do not return for the follow-up imaging they actually need. Explaining that the valve changes are common with aging, that they are worth monitoring every several years, and that the bigger clinical priority is managing standard cardiovascular risk factors seems to strike the right balance, though evidence on the best communication strategy remains thin.
Bicuspid Aortic Valves and Early Sclerosis
Most people are born with a three-leaflet aortic valve, but roughly one to two percent of the population has a bicuspid valve with only two leaflets. Bicuspid valves experience abnormal mechanical stress and tend to develop calcification and sclerosis much earlier in life, often by the 40s or 50s rather than the 70s or 80s. The genetic overlap between bicuspid valve disease and calcific aortic valve disease, as seen with the PALMD and TEX41 loci, suggests shared developmental pathways.23Nature Communications. Genome-wide analysis yields new loci associating with aortic valve stenosis If you are younger than 60 and told you have aortic sclerosis, your clinician should investigate whether you have a bicuspid valve, because the monitoring timeline and likelihood of eventually needing surgery are substantially different from the typical age-related variety.